DSpace university logo mark
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 110 医歯薬学総合研究科 > 110 学位論文 > 110 学位論文 >

Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire

ファイル 記述 サイズフォーマット
ISYK919_Nozaki.pdf229.03 kBAdobe PDF本文ファイル

タイトル: Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire
その他のタイトル: 新規質問票NADIQを用いた中枢性尿崩症患者のQOL評価
著者: 野崎, 彩
著者(別表記) : Nozaki, Aya
発行日: 2017年 3月21日
出版者: Springer
引用: Nagasaki University (長崎大学), 博士(医学) (2017-03-21)
抄録: Central diabetes insipidus (CDI) is characterized by polyuria and polydipsia due to a deficiency of vasopressin. Currently, the treatment goal for CDI is improvement of quality of life (QOL) by desmopressin (DDAVP) without developing hyponatremia. However, there is no reliable measure for QOL in CDI patients. We evaluate our original questionnaire for QOL, consisting of 12 questions focusing on polyuria, polydipsia, and DDAVP treatment, in CDI patients who underwent a switch from nasal spray to oral disintegrating tablets of DDAVP. Twenty-five CDI patients under nasal DDAVP treatment, six with newly developed CDI, and 18 healthy individuals without known polyuric/polydipsic disorders as control subjects were enrolled. QOL scores were determined by our questionnaire at the enrollment and 3 months after the start of oral DDAVP treatment and were examined by the Wilcoxon signed-rank test. Eleven questions detected improvement in QOL. The sum of the QOL scores of the eleven questions increased from 29.2 ± 5.6 under nasal to 36.8 ± 4.5 under oral DDAVP (p < 0.001). There were no clinically relevant changes in serum levels of Na. After eliminating two questions about DDAVP treatment, the sum of QOL scores was 15.3 ± 6.5 in untreated CDI patients, 24.4 ± 5.2 in those with nasal treatment, 28.9 ± 4.9 in those with oral DDAVP, and 29.5 ± 3.6 in healthy controls. The difference among groups was significant (p < 0.05 in Steel–Dwass test) except between patients treated with oral DDAVP and healthy controls. Our questionnaire can be used to accurately assess QOL in CDI patients.
記述: 長崎大学学位論文 学位記番号:博(医歯薬)甲第919号 学位授与年月日:平成29年3月21日 / Author: Aya Nozaki, Takao Ando, Satoru Akazawa, Tsuyoshi Satoh, Ikuko Sagara, Ichiro Horie, Misa Imaizumi, Toshiro Usa, Robert T. Yanagisawa, Atsushi Kawakami / Citation: Endocrine, 51(1), pp.140-147; 2016
キーワード: Diabetes insipidus / Quality of life / Questionnaire / Desmopressin
URI: http://hdl.handle.net/10069/37092
ISSN: 1355008X
DOI: 10.1007/s12020-015-0637-3
権利: © Springer Science+Business Media New York 2015 / The final publication is available at link.springer.com
資料タイプ: Thesis or Dissertation
原稿種類: ETD
出現コレクション:110 学位論文

引用URI : http://hdl.handle.net/10069/37092



Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace